Lannett launches authorized generic of Tirosint

Lannett is expanding its portfolio of medications for thyroid deficiency, with the launch of an authorized generic of Tirosint. The company entered into an exclusive U.S. distribution agreement with IBSA Institut Biochimique, a global pharmaceutical company headquartered in Switzerland. Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not disclosed.

"Currently, we believe we are the sole provider of all 12 currently marketed dosage strengths for generic levothyroxine capsules," Lannett CEO Tim Crew said. "We expect another supplier to enter the market with a subset of dosage strengths, in due course. Thereafter, we would be one of only two suppliers of the generic alternative for an extended period of time, given our understanding of the intellectual property estate associated with Tirosint. Levothyroxine capsules complements and expands our portfolio of medications for thyroid deficiency."

Levothyroxine sodium capsules had a market value of approximately $111 million for the 12 months ended September 2020, according to IQVIA, although actual generic market values are expected to be lower.